SIMPLYBOOK.ME
8.2.2021 19:31:11 CET | Business Wire | Press release
The SimplyBook.me appointment scheduling system, originally created as a solution for a popular tire workshop in Iceland, is now processing millions of Covid vaccination and Covid test bookings worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005729/en/
Early 2020, when the pandemic started to spread, the management and staff of SimplyBook.me worried how it might affect the company and its future with the core clients being smaller service businesses. The management team took the stand to use the company's reserve funds to keep all its qualified staff, even though the situation might drag on for months. At the same time, work began to evaluate if SimplyBook.me could find its place in the fight against the spread of the virus.
At this point, widespread Covid testing had not begun, and social distancing and masks were the order of the day. The team immediately identified opportunities to help with organising social distancing as well as Covid testing. Despite the bombardment of cancellation requests from smaller service businesses using the software that experienced lockdowns and inability to function, the COVID-related services continued to grow stronger.
NHS in the UK approached SimplyBook.me during the summer of 2020 as they needed a booking solution to help them organise Covid testing in one of their areas. We jumped on the opportunity and fine-tuned our software to customise to their needs. The results spoke for themselves, and more and more NHS trusts joined up to use the software. When it became apparent that the UK was going to be the first to start vaccinating, SimplyBook.me put the full force of their development and support teams on setting up the software so it would work for vaccinations in the best way possible.
"The project leader and team we've been working with at the NHS, are outstanding in their work and organisation. I sincerely hope the UK administration understands the quality of all the people working behind the scenes so that everything works as planned. They are incredibly professional and demand nothing less than perfection" said Ingvar Gudmundsson founder and VP-Sales at SimplyBook.me. "It is a privilege to work with such dedicated people who are doing their utmost to deliver the best."
"It is now early 2021, and we are proud to have taken a direct part in the fight against the virus throughout the past ten months. The cherry on the top is knowing that we are now being used for vaccination scheduling, processing millions of bookings in only the first few weeks since it started. We were always confident that we had built a great flexible software, adaptable to be used in all sorts of situations. This original vision has helped us grow faster than ever, keep all staff fully employed, and finally be at the forefront in the fight against the biggest plague of the last century."
________________________________________________________________________
SimplyBook.me is one of the world's top booking systems – a 360-degree software service which acts as a growth tool for SMEs, health organisations and educational institutions. The SimplyBook.me mission is bringing people and service businesses together by enabling them to easily book their services online no matter where, when or which.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005729/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
